RJA
CYCN icon

Raymond James & Associates’s Cyclerion Therapeutics CYCN Stock Holding History

Raymond James & Associates’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,079
Closed -$128K – 3600
2020
Q2 		$128K Buy
+1,079
New +$90.2K ﹤0.01% 3239

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's CYCN Position: Q3 2020 in Review

Raymond James & Associates sold out of Cyclerion Therapeutics (CYCN) in Q3 2020, closing a stake of 1,079 shares — an estimated $128K sold.

Raymond James & Associates first reported a position in CYCN in Q2 2020 and held it in 1 quarter. The position peaked at $128K in Q2 2020. 73 funds tracked by Wall St. Rank hold CYCN as of Q3 2020.

  • Raymond James & Associates reported no remaining Cyclerion Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Raymond James & Associates sold 1,079 Cyclerion Therapeutics shares in Q3 2020, an estimated $128K.
  • Raymond James & Associates first reported a position in Cyclerion Therapeutics in Q2 2020 and held it in 1 quarter.
  • Raymond James & Associates's Cyclerion Therapeutics position peaked at $128K in Q2 2020.
  • 73 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2020.

Based on Raymond James & Associates's 13F filing for Q3 2020, filed 4 Nov 2020.